Association of gliclazide and left ventricular mass in type 2 diabetic patients

Nan Hung Pan, Tsung-Ming Lee, Mei S. Lin, Chen-Ling Huang, Nen Chung Chang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Diabetes is a state of increased oxidant stress and there is evidence that oxidation may play a role in the genesis of higher left ventricular mass. Gliclazide has been shown to possess free radical scavenging properties. We assessed whether gliclazide may have a beneficial effect on left ventricular mass via reducing 8-iso-prostaglandin F concentrations, a reliable marker of oxidant injury. A total of 41 patients were randomized into two groups. All patients had been taking glibenclamide for more than 3 months before being randomized to switch either an equipotent dose of gliclazide (n = 21) or to continue on glibenclamide (n = 20). Baseline characteristics were similar in both groups. At 6 months, gliclazide-treated patients showed a significant regression in left ventricular mass index compared with the glibenclamide-treated group (-16% versus 3%, P = 0.003). Gliclazide patients had significantly lower plasma 8-iso-prostaglandin F compared with baseline (299 ± 101 pg/ml versus 400 ± 112 pg/ml, P = 0.001) and the glibenclamide-treated patients (299 ± 101 pg/ml versus 388 ± 114 pg/ml, P = 0.01) after 6-month therapy. The magnitude of left ventricular mass index regression correlated univariately with the magnitude of inhibition of 8-iso-prostaglandin F formation (r = 0.74, P <0.0001). Multivariate analysis revealed that regression of left ventricular mass index significantly correlated with the changes of 8-iso-prostaglandin F (P <0.0001, adjusted R2 = 0.55). Our findings demonstrated for the first time that in addition to its primary hypoglycemia, gliclazide may have an additional effect on reducing left ventricular mass, possibly through attenuation of free radical formation.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalDiabetes Research and Clinical Practice
Volume74
Issue number2
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Gliclazide
Dinoprost
Glyburide
Oxidants
Free Radicals
Hypoglycemia
Multivariate Analysis
Wounds and Injuries

Keywords

  • 8-Iso-prostaglandin F
  • Diabetes mellitus
  • Glibenclamide
  • Gliclazide
  • Left ventricular mass

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Association of gliclazide and left ventricular mass in type 2 diabetic patients. / Pan, Nan Hung; Lee, Tsung-Ming; Lin, Mei S.; Huang, Chen-Ling; Chang, Nen Chung.

In: Diabetes Research and Clinical Practice, Vol. 74, No. 2, 11.2006, p. 121-128.

Research output: Contribution to journalArticle

@article{79506203358a46489cc4b06d1345a67d,
title = "Association of gliclazide and left ventricular mass in type 2 diabetic patients",
abstract = "Diabetes is a state of increased oxidant stress and there is evidence that oxidation may play a role in the genesis of higher left ventricular mass. Gliclazide has been shown to possess free radical scavenging properties. We assessed whether gliclazide may have a beneficial effect on left ventricular mass via reducing 8-iso-prostaglandin F2α concentrations, a reliable marker of oxidant injury. A total of 41 patients were randomized into two groups. All patients had been taking glibenclamide for more than 3 months before being randomized to switch either an equipotent dose of gliclazide (n = 21) or to continue on glibenclamide (n = 20). Baseline characteristics were similar in both groups. At 6 months, gliclazide-treated patients showed a significant regression in left ventricular mass index compared with the glibenclamide-treated group (-16{\%} versus 3{\%}, P = 0.003). Gliclazide patients had significantly lower plasma 8-iso-prostaglandin F2α compared with baseline (299 ± 101 pg/ml versus 400 ± 112 pg/ml, P = 0.001) and the glibenclamide-treated patients (299 ± 101 pg/ml versus 388 ± 114 pg/ml, P = 0.01) after 6-month therapy. The magnitude of left ventricular mass index regression correlated univariately with the magnitude of inhibition of 8-iso-prostaglandin F2α formation (r = 0.74, P <0.0001). Multivariate analysis revealed that regression of left ventricular mass index significantly correlated with the changes of 8-iso-prostaglandin F2α (P <0.0001, adjusted R2 = 0.55). Our findings demonstrated for the first time that in addition to its primary hypoglycemia, gliclazide may have an additional effect on reducing left ventricular mass, possibly through attenuation of free radical formation.",
keywords = "8-Iso-prostaglandin F, Diabetes mellitus, Glibenclamide, Gliclazide, Left ventricular mass",
author = "Pan, {Nan Hung} and Tsung-Ming Lee and Lin, {Mei S.} and Chen-Ling Huang and Chang, {Nen Chung}",
year = "2006",
month = "11",
doi = "10.1016/j.diabres.2006.03.009",
language = "English",
volume = "74",
pages = "121--128",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Association of gliclazide and left ventricular mass in type 2 diabetic patients

AU - Pan, Nan Hung

AU - Lee, Tsung-Ming

AU - Lin, Mei S.

AU - Huang, Chen-Ling

AU - Chang, Nen Chung

PY - 2006/11

Y1 - 2006/11

N2 - Diabetes is a state of increased oxidant stress and there is evidence that oxidation may play a role in the genesis of higher left ventricular mass. Gliclazide has been shown to possess free radical scavenging properties. We assessed whether gliclazide may have a beneficial effect on left ventricular mass via reducing 8-iso-prostaglandin F2α concentrations, a reliable marker of oxidant injury. A total of 41 patients were randomized into two groups. All patients had been taking glibenclamide for more than 3 months before being randomized to switch either an equipotent dose of gliclazide (n = 21) or to continue on glibenclamide (n = 20). Baseline characteristics were similar in both groups. At 6 months, gliclazide-treated patients showed a significant regression in left ventricular mass index compared with the glibenclamide-treated group (-16% versus 3%, P = 0.003). Gliclazide patients had significantly lower plasma 8-iso-prostaglandin F2α compared with baseline (299 ± 101 pg/ml versus 400 ± 112 pg/ml, P = 0.001) and the glibenclamide-treated patients (299 ± 101 pg/ml versus 388 ± 114 pg/ml, P = 0.01) after 6-month therapy. The magnitude of left ventricular mass index regression correlated univariately with the magnitude of inhibition of 8-iso-prostaglandin F2α formation (r = 0.74, P <0.0001). Multivariate analysis revealed that regression of left ventricular mass index significantly correlated with the changes of 8-iso-prostaglandin F2α (P <0.0001, adjusted R2 = 0.55). Our findings demonstrated for the first time that in addition to its primary hypoglycemia, gliclazide may have an additional effect on reducing left ventricular mass, possibly through attenuation of free radical formation.

AB - Diabetes is a state of increased oxidant stress and there is evidence that oxidation may play a role in the genesis of higher left ventricular mass. Gliclazide has been shown to possess free radical scavenging properties. We assessed whether gliclazide may have a beneficial effect on left ventricular mass via reducing 8-iso-prostaglandin F2α concentrations, a reliable marker of oxidant injury. A total of 41 patients were randomized into two groups. All patients had been taking glibenclamide for more than 3 months before being randomized to switch either an equipotent dose of gliclazide (n = 21) or to continue on glibenclamide (n = 20). Baseline characteristics were similar in both groups. At 6 months, gliclazide-treated patients showed a significant regression in left ventricular mass index compared with the glibenclamide-treated group (-16% versus 3%, P = 0.003). Gliclazide patients had significantly lower plasma 8-iso-prostaglandin F2α compared with baseline (299 ± 101 pg/ml versus 400 ± 112 pg/ml, P = 0.001) and the glibenclamide-treated patients (299 ± 101 pg/ml versus 388 ± 114 pg/ml, P = 0.01) after 6-month therapy. The magnitude of left ventricular mass index regression correlated univariately with the magnitude of inhibition of 8-iso-prostaglandin F2α formation (r = 0.74, P <0.0001). Multivariate analysis revealed that regression of left ventricular mass index significantly correlated with the changes of 8-iso-prostaglandin F2α (P <0.0001, adjusted R2 = 0.55). Our findings demonstrated for the first time that in addition to its primary hypoglycemia, gliclazide may have an additional effect on reducing left ventricular mass, possibly through attenuation of free radical formation.

KW - 8-Iso-prostaglandin F

KW - Diabetes mellitus

KW - Glibenclamide

KW - Gliclazide

KW - Left ventricular mass

UR - http://www.scopus.com/inward/record.url?scp=33751114455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751114455&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2006.03.009

DO - 10.1016/j.diabres.2006.03.009

M3 - Article

C2 - 16631274

AN - SCOPUS:33751114455

VL - 74

SP - 121

EP - 128

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -